Add BrightSurf on Google Email

Cost, bleeding cited as major reasons for not taking newer anti-coagulant as prescribed

A recent study found that 26-45% of people with atrial fibrillation fail to adhere to their prescribed direct-acting oral anticoagulants due to cost and bleeding concerns. Researchers interviewed 42 adults who had stopped or reduced dosing, citing these reasons as major barriers to adherence.

SourceUniversity of California - Los Angeles Health Sciences·JournalJournal of the American Geriatrics Society·TypeSurvey·DateSep 2, 2021

Two PrEP medications are now available. Equally safe/effective. The biggest difference? The price tag.

A new study found that only 7% of patients who switched from Truvada to Descovy had a documented clinical reason for doing so, highlighting the need for cost-effective PrEP options. The significant price difference between the two medications may be a major barrier to broad and equitable PrEP use in the US.

SourceHarvard Pilgrim Health Care Institute·JournalOpen Forum Infectious Diseases·DateAug 5, 2021

Research shows employer-based weight management program with access to anti-obesity medications results in greater weight loss

A study by Cleveland Clinic found that combining a weight management program with FDA-approved anti-obesity medications leads to significant weight loss among adults with obesity. The research showed that participants who had access to the medications averaged -7.7% weight loss at 12 months, compared to -4.2% in those without medication.

SourceCleveland Clinic·JournalJAMA Network Open·DateJul 20, 2021

What are the effects of inappropriate prescriptions in older adults?

A study published in British Journal of Clinical Pharmacology found that potentially inappropriate prescribing is associated with functional decline, falls and hospital admissions. Decision support tools can help reduce medication-related harm, but comprehensive assessment of medication use during care transitions is crucial.

SourceWiley·JournalBritish Journal of Clinical Pharmacology·DateMay 19, 2021

Better treatment for miscarriage patients is more cost effective than standard NHS treatment

A new study published in the British Journal of Obstetrics and Gynaecology found that a combined drug treatment for missed miscarriage is more effective and cheaper than current standard medication. The treatment, combining mifepristone and misoprostol, was on average £182 cheaper per successfully managed miscarriage.

SourceUniversity of Birmingham·JournalBritish Journal of Obstetrics and Gynaecology·DateMay 11, 2021

Gout treatment success doubled by combining two drugs, study finds

A recent study found that combining two medications can double the effectiveness of gout treatment. Researchers at Michigan Medicine discovered that adding immunomodulation drug mycophenolate mofetil to Pegloticase infusions significantly increased the success rate, reducing urate levels below the therapeutic target in 86% of patients.

SourceMichigan Medicine - University of Michigan·JournalArthritis & Rheumatology·DateMay 11, 2021

Original investigation: When drug companies raise list prices, out-of-pocket costs for patients

A new study by Dr. Benjamin Rome and colleagues found that over half of patients experience increases in out-of-pocket costs when drug prices increase, with some patients facing 15% hikes. The study, published in JAMA Network Open, analyzed 79 brand-name drugs and found average out-of-pocket costs rose 3.5% from 2015 to 2017.

SourceBrigham and Women's Hospital·JournalJAMA Network Open·DateMay 4, 2021

Drug coupons and vouchers cover only a sliver of prescription drugs

A study from Johns Hopkins Bloomberg School of Public Health analyzed tens of millions of pharmacy transactions to understand the use of vouchers and coupons. The researchers found that these offsets are concentrated among a small number of drugs, covering about half of their costs, with manufacturer-provided offsets fully covering pat...

SourceJohns Hopkins Bloomberg School of Public Health·JournalJAMA Internal Medicine·DateMar 29, 2021

harp reductions in costs of producing cannabis, fentanyl likely to spur widespread changes in use, dependence

A new analysis by Carnegie Mellon University professor Jonathan Caulkins explores the effects of reduced production costs on cannabis and opioid use. Sharp declines in prices may alter consumption patterns and lead to changes in drug markets, including reduced violence and disruption of criminal organizations.

SourceCarnegie Mellon University·JournalInternational Journal of Drug Policy·DateMar 10, 2021

Most dollars spent on top-selling orphan drugs don't go to treat people with rare diseases

A new study by University of Michigan and Boston University researchers found that only 21% of dollars spent on 15 top-selling partial orphan drugs went to treating rare diseases, while 70% went to common diseases. This raises questions about whether the benefits of orphan drug status are always warranted for these drugs.

Hide-and-seek can lead to higher drug prices

A study by the University of Zurich found that 63% of drugs with rebates granted in Switzerland have low clinical benefits, while 49% have no significant benefit. The research highlights the need for transparent cooperation between European countries to improve drug pricing and patient access.

SourceUniversity of Zurich·JournalThe Lancet Regional Health - Europe·DateFeb 17, 2021

Shelf-stable vaccines avoid waste, expand access

Researchers developed a new manufacturing platform using freeze-dried components that can quickly make vaccines on demand. The platform eliminates the need for complex supply chains and refrigeration, making it ideal for low-resource settings. This innovation has the potential to expand access to life-saving medications.

SourceNorthwestern University·JournalJournal of Mathematical Sciences Advances and Applications·DateFeb 3, 2021

The true cost of chemotherapy

A new study from the University of East Anglia estimates that breast cancer chemotherapy in the UK results in over £248 million in annual costs. These costs include lost productivity and personal expenses such as wigs and medication. Better targeting of treatment could help reduce these unnecessary costs.

SourceUniversity of East Anglia·JournalBMJ Open·DateJan 4, 2021